InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,646.85
(
0.22%
)
US TECH 100
19,188.40
(
-0.06%
)
Dow Jones
41,306.96
(
0.32%
)
Brent Oil
80.41
(
2.60%
)
Bitcoin
63,729.46
(
-0.98%
)
Post# of 252973
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120332
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 94439

Monday, 04/19/2010 4:26:37 PM

Monday, April 19, 2010 4:26:37 PM

Post# of 252973
HGSI: This can perhaps be construed as good news for investors insofar as NVS/HGSI presumably won’t waste any more money on the Albuferon program. Albuferon wasn’t going to be a commercial success in any case.

Although the BLA with the FDA is still pending, I’m taking the liberty of moving Albuferon from paragraph #2 to paragraph #6 (back-burner programs) in the next revision of “HCV: Most Likely to Succeed.”


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up